How Rezdiffra (Resmetirom) Affects FibroScan / VCTE Scores

What Resmetirom Does to Liver Fat and Stiffness

Resmetirom selectively activates thyroid hormone receptor beta in hepatocytes, which drives mitochondrial fatty acid oxidation and reduces de novo lipogenesis. The net result is a measurable drop in intrahepatic triglyceride content. Because FibroScan's controlled attenuation parameter (CAP) directly reflects hepatic steatosis, CAP values fall as resmetirom clears fat from the liver 1.

Liver stiffness measurement (LSM) responds more slowly. LSM on VCTE reflects a combination of fibrosis, inflammation, and congestion. Resmetirom's anti-inflammatory effects (reduced ballooning, lower lobular inflammation scores on biopsy) contribute to early LSM improvement, while true collagen remodeling takes longer. In MAESTRO-NASH, the 100 mg group showed statistically significant reductions in multiple non-invasive fibrosis markers, including enhanced liver fibrosis (ELF) score and FibroMeter, which correlate closely with VCTE-derived stiffness 1. Patients with baseline LSM values in the 8 to 14 kPa range (consistent with F2-F3 fibrosis) showed the most consistent directional improvement, though individual responses varied.

MAESTRO-NASH Trial Data on Fibrosis and Steatosis Endpoints

The MAESTRO-NASH phase 3 trial (N=966) randomized adults with biopsy-confirmed MASH and fibrosis stage F1B through F3 to resmetirom 80 mg, 100 mg, or placebo for 52 weeks 1. The co-primary endpoints were MASH resolution without worsening of fibrosis and fibrosis improvement by at least one stage without worsening of NASH Activity Score.

Results were clear. At week 52, MASH resolution occurred in 25.9% of the 80 mg group and 29.9% of the 100 mg group, compared with 9.7% on placebo (P<0.001 for both comparisons) 1. Fibrosis improvement of at least one stage occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% on placebo (P<0.01 for 80 mg; P<0.001 for 100 mg) 1.

MRI-derived proton density fat fraction (MRI-PDFF), the imaging gold standard for hepatic fat, decreased by a relative 32.9% with 80 mg and by a relative 42.5% with 100 mg at 52 weeks. The absolute reduction at 100 mg was approximately 5.0 percentage points versus 0.1 percentage points for placebo 1. These MRI-PDFF shifts translate predictably to CAP reductions on VCTE, since both modalities measure hepatic triglyceride content through different physics.

Dr. Stephen Harrison, the trial's principal investigator and medical director of Pinnacle Clinical Research, stated: "The magnitude of fat reduction we observed with resmetirom at 52 weeks is among the largest reported for any oral MASH therapy, and non-invasive markers tracked consistently with biopsy-confirmed histologic improvement" 1.

How to Interpret FibroScan Changes on Resmetirom

FibroScan produces two values that matter during resmetirom therapy. CAP (measured in dB/m) quantifies steatosis. LSM (measured in kPa) estimates fibrosis and inflammation. Both can shift on treatment, but they move on different timelines and for different biological reasons.

CAP changes appear first. Because resmetirom directly accelerates hepatic fat clearance through THR-beta-mediated beta-oxidation, CAP reductions may be detectable within 12 to 24 weeks of therapy initiation 2. A CAP drop of 30 dB/m or more generally corresponds to a meaningful reduction in steatosis grade. Patients starting with CAP values above 300 dB/m (S2-S3 steatosis) tend to show the largest absolute declines.

LSM changes develop more gradually. A drop in LSM during the first 6 months of therapy likely reflects reduced necroinflammation rather than true fibrosis regression. The American Association for the Study of Liver Diseases (AASLD) practice guidance on MASLD notes that "changes in liver stiffness by VCTE should be interpreted cautiously in the context of concurrent changes in body weight, aminotransferase levels, and metabolic parameters" 3. This caution applies directly to resmetirom monitoring: ALT levels drop on therapy (mean reduction of roughly 15 to 20 U/L at 100 mg), which itself lowers LSM independent of fibrotic change.

A practical threshold: if LSM drops by 20% or more from baseline and ALT normalizes, the combination supports a favorable treatment response. If LSM remains flat but CAP drops and ALT normalizes, the therapy is still likely working on steatosis and inflammation, with fibrosis remodeling potentially lagging.

Monitoring Timeline: When to Repeat FibroScan

No regulatory body has issued a rigid FibroScan schedule specifically for resmetirom. The following timeline reflects the approach used in MAESTRO-NASH and adapted by hepatology practices managing Rezdiffra patients.

Baseline (before or at treatment start): Obtain a fasting FibroScan with both LSM and CAP. Record body weight, ALT, AST, and lipid panel. These baseline values are the comparator for all future assessments 1.

Month 3: Check liver function tests (ALT, AST, bilirubin) per the Rezdiffra prescribing information, which mandates hepatic safety monitoring. A FibroScan is optional at this point but may be ordered if the clinician wants early steatosis data 4.

Month 6: Repeat FibroScan. At this timepoint, CAP should show measurable decline in responders. LSM may begin to trend downward. Compare with baseline values.

Month 12: Repeat FibroScan. This aligns with the MAESTRO-NASH 52-week primary endpoint assessment. Both LSM and CAP changes at this interval are clinically meaningful and can inform continuation decisions.

Annually thereafter: Continue annual VCTE monitoring. The AASLD suggests that serial non-invasive testing can reduce the need for repeat liver biopsy in patients on pharmacotherapy for MASH 3.

Factors That Can Confound FibroScan Readings During Treatment

Several variables can inflate or deflate FibroScan values independent of resmetirom's true hepatic effect. Clinicians and patients should account for these when interpreting results.

Fasting status. VCTE measurements obtained in a non-fasting state can read 1 to 2 kPa higher for LSM and 10 to 30 dB/m higher for CAP compared to fasting values. The European Association for the Study of the Liver (EASL) recommends a minimum 2-hour fast, ideally 3 hours, before FibroScan 5. All follow-up scans should replicate the fasting conditions used at baseline.

Body weight changes. Resmetirom can produce modest weight loss (1 to 3 kg over 52 weeks in MAESTRO-NASH). If a patient is simultaneously using a GLP-1 receptor agonist for obesity or type 2 diabetes, the combined weight loss may independently reduce CAP and LSM. This does not invalidate the FibroScan trend, but it means attributing the entire improvement to resmetirom alone is not straightforward 6.

Aminotransferase fluctuations. ALT flares from any cause (alcohol intake, new medication, viral hepatitis reactivation) can transiently spike LSM by 2 to 5 kPa. Repeat the scan after ALT stabilizes rather than assuming fibrosis progression.

Operator and probe variability. FibroScan results are most reliable with an IQR/median ratio below 30% and at least 10 valid measurements. Using the XL probe for patients with a skin-to-capsule distance above 25 mm is standard. Switching between M and XL probes across visits introduces systematic error 5.

The EASL-ALEH clinical practice guidelines state: "Interpretation of longitudinal VCTE values requires standardization of measurement conditions, including fasting status, probe selection, and operator experience, to minimize variability unrelated to disease progression or regression" 5.

Resmetirom's Mechanism: Why THR-Beta Activation Lowers Liver Fat

Thyroid hormone receptor beta is the dominant thyroid receptor isoform in the liver. When activated by resmetirom, it increases expression of genes governing mitochondrial fatty acid oxidation, including carnitine palmitoyltransferase 1A (CPT1A) and medium-chain acyl-CoA dehydrogenase (MCAD) 2. The result is accelerated clearance of intrahepatic triglycerides through beta-oxidation.

Simultaneously, THR-beta activation suppresses sterol regulatory element-binding protein 1c (SREBP-1c), which reduces de novo lipogenesis. The dual effect (more fat burned, less fat synthesized) produces the rapid steatosis reductions seen on MRI-PDFF and, by extension, on FibroScan CAP.

Resmetirom also lowers circulating LDL cholesterol by 13 to 16% and triglycerides by 16 to 20% at 52 weeks, consistent with hepatic THR-beta activation increasing LDL receptor expression and bile acid synthesis 1. These lipid effects are pharmacodynamic markers confirming target engagement. If a patient's LDL and triglycerides have not declined at 3 months, adherence should be reassessed before attributing a flat FibroScan to treatment failure.

The selectivity for THR-beta over THR-alpha is what separates resmetirom from levothyroxine or liothyronine. THR-alpha predominates in the heart and bone. By sparing THR-alpha, resmetirom avoids tachycardia, bone loss, and the other systemic effects of thyroid hormone excess 2.

Who Benefits Most: Patient Selection and Expected FibroScan Response

The FDA approved Rezdiffra for adults with MASH and moderate to advanced liver fibrosis (stages F2 and F3). This maps to baseline FibroScan LSM values roughly between 8.0 and 14.9 kPa (using the Baveno VII consensus thresholds for MASLD) 7.

Patients with F2 fibrosis and high baseline steatosis (CAP above 300 dB/m) are likely to see the most dramatic FibroScan changes because they have the most fat to lose. Patients with F3 fibrosis may show CAP improvement with a slower or more modest LSM decline, since established bridging fibrosis takes longer to remodel than the early perisinusoidal fibrosis of F2.

Rezdiffra is not approved for compensated cirrhosis (F4). The MAESTRO-NASH trial excluded patients with cirrhosis from the primary efficacy analysis. Patients with LSM above 20 kPa on baseline FibroScan should be evaluated for cirrhosis with additional workup rather than started empirically on resmetirom 4.

Age and sex do not appear to modify the FibroScan response in a clinically significant way based on available subgroup analyses, though data remain limited in patients over 75 and in those with BMI above 45.

Combining Resmetirom with Other MASH Therapies and FibroScan Interpretation

Many patients receiving Rezdiffra are simultaneously taking pioglitazone, vitamin E, or a GLP-1 receptor agonist. Each of these therapies independently affects hepatic fat and inflammation, which means FibroScan readings on combination therapy reflect a composite drug effect.

Semaglutide (2.4 mg weekly) reduced hepatic steatosis by approximately 5 percentage points at 72 weeks in the STEP-NASH substudy, producing CAP declines comparable to resmetirom alone 8. When combined, the two mechanisms (GLP-1 mediated appetite and insulin sensitization, plus THR-beta mediated fat oxidation) could theoretically produce additive or even synergistic fat reduction. Clinical trial data on the combination are not yet published, but real-world hepatology practices are already prescribing both.

Pioglitazone reduces LSM partly through anti-inflammatory effects on stellate cells. Adding resmetirom to pioglitazone could accelerate both CAP and LSM improvement. Vitamin E's antioxidant effect on lobular inflammation may reduce LSM independent of fibrosis regression 3.

The practical takeaway: document all concurrent hepatoprotective therapies when ordering follow-up FibroScan. A multidrug regimen that produces a 40 dB/m CAP drop and a 3 kPa LSM drop at 12 months is a strong signal of histologic improvement, but it cannot be attributed to resmetirom alone without controlled comparison.

Safety Signals Relevant to FibroScan Monitoring

The Rezdiffra label carries a warning for hepatotoxicity. In MAESTRO-NASH, ALT elevations above 3 times the upper limit of normal occurred in 3.4% of the 80 mg group and 5.2% of the 100 mg group versus 0.8% on placebo 4. These elevations were generally asymptomatic and reversible with dose interruption or discontinuation.

An ALT spike during resmetirom therapy will confound concurrent FibroScan LSM readings. If a routine month-3 blood draw reveals ALT above 3x ULN, postpone any planned FibroScan until transaminases normalize. Measuring LSM during an ALT flare will overestimate stiffness and may trigger unnecessary concern about fibrosis progression 5.

Other reported adverse events (diarrhea in 27% at 100 mg, nausea in 19%) do not directly affect FibroScan readings but may influence adherence. A patient who stops taking resmetirom due to GI side effects will not show FibroScan improvement. Confirming medication adherence before interpreting a static FibroScan is a simple but commonly overlooked step.